Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 4
Submit an article Journal homepage
878
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Vemurafenib and ipilimumab: A promising combination? Results of a case series

Jessica C. HasselDepartment of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GermanyCorrespondence[email protected]
,
Sophia B. LeeDepartment of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
,
Frank MeissDepartment of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany
,
Friedegund MeierDepartment of Dermatology, University Hospital Tübingen, Tübingen, Germany
,
Antonia Dimitrakopoulou-StraussClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
,
Dirk JägerDepartment of Medical Oncology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
&
Alexander H. EnkDepartment of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
 show all
Article: e1101207 | Received 10 Aug 2015, Accepted 23 Sep 2015, Published online: 08 Apr 2016

References

  • Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
  • Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E et al. Dabrafenib in BRAF-mutated metastatic melanoma. A multicenter, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-65; PMID:22735384; http://dx.doi.org/10.1016/S0140-6736(12)60868-X
  • Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30-9; PMID:25399551; http://dx.doi.org/10.1056/NEJMoa1412690
  • Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA et al. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 2015; 121:3826-35; PMID:26218930; http://dx.doi.org/10.1002/cncr.29586
  • Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
  • Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014; 63:449-58; PMID:24609989; http://dx.doi.org/10.1007/s00262-014-1528-9
  • Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc-1302338
  • Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014; 120:1695-701; PMID:24577748; http://dx.doi.org/10.1002/cncr.28620
  • Ribas A, Chapman P, McArthur G, Robert C, Sosman JA, Hauschild A, Donica M, Antic V, Makrutzki M, Flaherty KT. Long-term response in patients with BRAFV600 mutation-positive metastatic melanoma who received vemurafenib: pooled data analyses from BRIM2 and BRIM3. Pigment Cell Melanom Res 2014; 27:1179; http://dx.doi.org/10.1111/pcmr.12317
  • Frederick D, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favourable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-31; PMID:23307859; http://dx.doi.org/10.1158/1078-0432.CCR-12-1630
  • Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockage. Cancer Immunology Res 2014; 2:643-54; http://dx.doi.org/10.1158/2326-6066.CIR-13-0215
  • Minor DR, Puzanov I, Callahan MK, Hug BA, Hoos A. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res 2015; 28:611-2; PMID:25996827; http://dx.doi.org/10.1111/pcmr.12383
  • Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 2015; 7:279ra41; PMID:25787767; http://dx.doi.org/10.1126/scitranslmed.aaa4691
  • Ribas A, Butler M, Lutzky J, Lawrence DP, Robert C, Miller W, Linette GP, Ascierto PA, Kuzel T, Algazi AP et al. J Clin Oncol 2015; 33:1865-6, suppl; abstr 3003.Tbl.1: Patient characteristics; PMID:25667273; http://dx.doi.org/10.1200/JCO.2014.59.5041

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.